FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2781307003> ?p ?o ?g. }

• W2781307003 endingPage "e9443" @default.
• W2781307003 startingPage "e9443" @default.
• W2781307003 abstract "Introduction: Few studies have assessed the efficacy and safety of micafungin in patients with proven or probable invasive aspergillosis (IA). This was the aim of the current study, which was conducted in 22 hospitals in China, where micafungin was approved for treatment of IA in 2006. Methods: This was a non-comparative, phase IV open-label study (NCT02646774). Eligible patient were adults with proven or probable IA. Efficacy endpoints included rates of overall treatment success (primary endpoint) and clinical improvement, fungal clearance, mortality, and the site of Aspergillus infection (all secondary endpoints). Safety endpoints included incidences of treatment-emergent adverse events (TEAEs), serious AEs (SAEs), and adverse drug reactions (ADRs). These endpoints were reported descriptively with associated 95% confidence intervals (CI); no hypotheses were tested. Results: The study was discontinued early due to low patient recruitment, which did not allow for the planned sample size to be reached. In total, 68 patients were enrolled: 42 into the full analysis set (for efficacy) and 61 into the safety analysis set. All patients were Han Chinese; the majority were male (n = 26; 61.9%) and ≤60 years of age (n = 35; 83.3%). Rates of overall treatment success, clinical improvement, fungal clearance, and mortality were 45.2% (n = 19/42; 95% CI: 29.85–61.33); 59.5% (n = 25/42; 95% CI: 43.28–74.37), 80.0% (n = 4/5; 95% CI: 28.36–99.49), and 7.1% (n = 3/42; 95% CI: 1.50–19.48), respectively. All patients were diagnosed with pulmonary Aspergillus infection. Overall, 155 TEAEs and 8 SAEs were reported by 37 (60.7%) and 7 (11.5%) patients. The most common TEAEs were decreased platelet count and fatigue (both n = 5; 8.2%) and the most common SAEs were intracranial hemorrhage and lung infection (n = 3; 4.9% and n = 2; 3.3%). Eight ADRs (n = 6; 9.8%) were reported but all were completely remitted or remitting during follow-up. Conclusions: Results suggest that micafungin is efficacious and well-tolerated in patients with proven or probable IA in China. However, these findings should be interpreted with care, due to the small number of patients included in this study. Further comparative trials should be used to confirm the efficacy and safety of micafungin in patients with proven or probable IA." @default.
• W2781307003 created "2018-01-05" @default.
• W2781307003 creator A5036049172 @default.
• W2781307003 creator A5042820937 @default.
• W2781307003 creator A5052251685 @default.
• W2781307003 creator A5055494772 @default.
• W2781307003 creator A5063089557 @default.
• W2781307003 creator A5068349871 @default.
• W2781307003 creator A5090241332 @default.
• W2781307003 date "2017-12-01" @default.
• W2781307003 modified "2023-10-17" @default.
• W2781307003 title "Efficacy and safety of micafungin for the treatment of patients with proven or probable invasive aspergillosis" @default.
• W2781307003 cites W1895673088 @default.
• W2781307003 cites W1968047266 @default.
• W2781307003 cites W1971395329 @default.
• W2781307003 cites W2005311388 @default.
• W2781307003 cites W2005803431 @default.
• W2781307003 cites W2019622698 @default.
• W2781307003 cites W2019694314 @default.
• W2781307003 cites W2054723603 @default.
• W2781307003 cites W2063203063 @default.
• W2781307003 cites W2076556610 @default.
• W2781307003 cites W2080468965 @default.
• W2781307003 cites W2082695689 @default.
• W2781307003 cites W2098438303 @default.
• W2781307003 cites W2110525699 @default.
• W2781307003 cites W2123134253 @default.
• W2781307003 cites W2127300067 @default.
• W2781307003 cites W2130180365 @default.
• W2781307003 cites W2137916005 @default.
• W2781307003 cites W2138426885 @default.
• W2781307003 cites W2142482664 @default.
• W2781307003 cites W2144677985 @default.
• W2781307003 cites W2146272590 @default.
• W2781307003 cites W2149642450 @default.
• W2781307003 cites W2149922169 @default.
• W2781307003 cites W2151483063 @default.
• W2781307003 cites W2159341432 @default.
• W2781307003 cites W2166734004 @default.
• W2781307003 cites W2167412063 @default.
• W2781307003 cites W2170595857 @default.
• W2781307003 cites W2173441685 @default.
• W2781307003 cites W2261914993 @default.
• W2781307003 cites W2470291098 @default.
• W2781307003 doi "https://doi.org/10.1097/md.0000000000009443" @default.
• W2781307003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6392632" @default.
• W2781307003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29384927" @default.
• W2781307003 hasPublicationYear "2017" @default.
• W2781307003 type Work @default.
• W2781307003 sameAs 2781307003 @default.
• W2781307003 citedByCount "3" @default.
• W2781307003 countsByYear W27813070032021 @default.
• W2781307003 countsByYear W27813070032022 @default.
• W2781307003 crossrefType "journal-article" @default.
• W2781307003 hasAuthorship W2781307003A5036049172 @default.
• W2781307003 hasAuthorship W2781307003A5042820937 @default.
• W2781307003 hasAuthorship W2781307003A5052251685 @default.
• W2781307003 hasAuthorship W2781307003A5055494772 @default.
• W2781307003 hasAuthorship W2781307003A5063089557 @default.
• W2781307003 hasAuthorship W2781307003A5068349871 @default.
• W2781307003 hasAuthorship W2781307003A5090241332 @default.
• W2781307003 hasBestOaLocation W27813070031 @default.
• W2781307003 hasConcept C126322002 @default.
• W2781307003 hasConcept C141071460 @default.
• W2781307003 hasConcept C16005928 @default.
• W2781307003 hasConcept C197934379 @default.
• W2781307003 hasConcept C203014093 @default.
• W2781307003 hasConcept C203092338 @default.
• W2781307003 hasConcept C2776391196 @default.
• W2781307003 hasConcept C2779020398 @default.
• W2781307003 hasConcept C2779548794 @default.
• W2781307003 hasConcept C2780690907 @default.
• W2781307003 hasConcept C44249647 @default.
• W2781307003 hasConcept C535046627 @default.
• W2781307003 hasConcept C71924100 @default.
• W2781307003 hasConceptScore W2781307003C126322002 @default.
• W2781307003 hasConceptScore W2781307003C141071460 @default.
• W2781307003 hasConceptScore W2781307003C16005928 @default.
• W2781307003 hasConceptScore W2781307003C197934379 @default.
• W2781307003 hasConceptScore W2781307003C203014093 @default.
• W2781307003 hasConceptScore W2781307003C203092338 @default.
• W2781307003 hasConceptScore W2781307003C2776391196 @default.
• W2781307003 hasConceptScore W2781307003C2779020398 @default.
• W2781307003 hasConceptScore W2781307003C2779548794 @default.
• W2781307003 hasConceptScore W2781307003C2780690907 @default.
• W2781307003 hasConceptScore W2781307003C44249647 @default.
• W2781307003 hasConceptScore W2781307003C535046627 @default.
• W2781307003 hasConceptScore W2781307003C71924100 @default.
• W2781307003 hasIssue "52" @default.
• W2781307003 hasLocation W27813070031 @default.
• W2781307003 hasLocation W27813070032 @default.
• W2781307003 hasLocation W27813070033 @default.
• W2781307003 hasOpenAccess W2781307003 @default.
• W2781307003 hasPrimaryLocation W27813070031 @default.
• W2781307003 hasRelatedWork W2002120878 @default.
• W2781307003 hasRelatedWork W2003938723 @default.
• W2781307003 hasRelatedWork W2022417792 @default.
• W2781307003 hasRelatedWork W2047967234 @default.

• next